Pure Global
NCT06361485

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

R3 Stem Cell·Phase 1·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Low Back Pain
Drug/Device/Intervention
Lumbar Injections with 10cc's of Wharton's Jelly Allograft
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
R3 Stem Cell
Location
Scottsdale,Beverly Hills,New York,Cleveland, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Mar 25, 2024
End date
Apr 01, 2028
Enrollment
100 participants
Primary outcome

C-reactive protein,Erythrocyte sedimentation rate,Alanine transaminase (ALT),Aspartate transaminase (AST),Alkaline phosphatase (ALP),Albumin,Creatinine,Blood Urea Nitrogen (BUN)

Summary

This is a Pilot Study that is an open label, prospective, non-controlled study in which the
 safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100
 participants suffering with low back pain.

ICD-10 classifications
Low back painPain in thoracic spineContusion of lower back and pelvisInjuries to the abdomen, lower back, lumbar spine and pelvisSprain and strain of lumbar spine
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06361485
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06361485 through Pure Global AI's free database. This Phase 1 trial is sponsored by R3 Stem Cell and is currently Recruiting. The study focuses on Low Back Pain. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.